← FDA DRUG APPROVALS

FDA ANDA · ANDA209619

OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

olopatadine hydrochloride ophthalmic

Sponsor: GLAND

APPLICATION
ANDA209619
TYPE
ANDA
ORIGINAL APPROVAL
2019-08-02
LATEST ACTION
2020-05-07
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Over-the-counter

Products

OLOPATADINE HYDROCHLORIDEOver-the-counter
OLOPATADINE HYDROCHLORIDE EQ 0.1% BASE · SOLUTION/DROPS · OPHTHALMIC

Approval history

2020-05-07Labeling · Supplement 1 · standardAP
2019-08-02UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →